174 related articles for article (PubMed ID: 15693644)
1. Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer.
Mavi A; Lakhani P; Zhuang H; Gupta NC; Alavi A
Radiol Clin North Am; 2005 Jan; 43(1):1-21, ix. PubMed ID: 15693644
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
[TBL] [Abstract][Full Text] [Related]
3. Role of
Delgado Bolton RC; Calapaquí-Terán AK; Giammarile F; Rubello D
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):229-233. PubMed ID: 31202725
[TBL] [Abstract][Full Text] [Related]
4. [PET in primary pulmonary or pleural cancer].
Talbot JN; Kerrou K; Grahek D; Balogova S; Gounant V; Lavole A; Gutman F; Aflalo-Hazan V; Raileanu I; Montravers F; Mayaud C
Presse Med; 2006 Sep; 35(9 Pt 2):1387-400. PubMed ID: 16969335
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.
Christensen JA; Nathan MA; Mullan BP; Hartman TE; Swensen SJ; Lowe VJ
AJR Am J Roentgenol; 2006 Nov; 187(5):1361-7. PubMed ID: 17056930
[TBL] [Abstract][Full Text] [Related]
6. Using neighborhood gray tone difference matrix texture features on dual time point PET/CT images to differentiate malignant from benign FDG-avid solitary pulmonary nodules.
Chen S; Harmon S; Perk T; Li X; Chen M; Li Y; Jeraj R
Cancer Imaging; 2019 Aug; 19(1):56. PubMed ID: 31420006
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management.
Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP
Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239
[TBL] [Abstract][Full Text] [Related]
8. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
[TBL] [Abstract][Full Text] [Related]
9. Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology.
Farid K; Poullias X; Alifano M; Regnard JF; Servois V; Caillat-Vigneron N; Petras S
Nucl Med Commun; 2015 Jul; 36(7):722-7. PubMed ID: 25793929
[TBL] [Abstract][Full Text] [Related]
10. FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review.
Groheux D; Quere G; Blanc E; Lemarignier C; Vercellino L; de Margerie-Mellon C; Merlet P; Querellou S
Diagn Interv Imaging; 2016 Oct; 97(10):1003-1017. PubMed ID: 27567555
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Fluorodeoxyglucose F18-Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules.
Maiga AW; Deppen SA; Mercaldo SF; Blume JD; Montgomery C; Vaszar LT; Williamson C; Isbell JM; Rickman OB; Pinkerman R; Lambright ES; Nesbitt JC; Grogan EL
JAMA Surg; 2018 Apr; 153(4):329-334. PubMed ID: 29117314
[TBL] [Abstract][Full Text] [Related]
12. Imaging in lung cancer: positron emission tomography scan.
Vansteenkiste JF
Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
[TBL] [Abstract][Full Text] [Related]
13. The role of ¹⁸F-FDG PET or ¹⁸F-FDG-PET/CT in the evaluation of solitary pulmonary nodules.
Li W; Pang H; Liu Q; Zhou J
Eur J Radiol; 2015 Oct; 84(10):2032-7. PubMed ID: 26094866
[TBL] [Abstract][Full Text] [Related]
14. Solitary pulmonary nodule evaluation in regions endemic for infectious diseases: Do regional variations impact the effectiveness of fluorodeoxyglucose positron emission tomography/computed tomography.
Purandare NC; Pramesh CS; Agarwal JP; Agrawal A; Shah S; Prabhash K; Karimundackal G; Jiwnani S; Tandon S; Rangarajan V
Indian J Cancer; 2017; 54(1):271-275. PubMed ID: 29199704
[TBL] [Abstract][Full Text] [Related]
15. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity.
Xiu Y; Bhutani C; Dhurairaj T; Yu JQ; Dadparvar S; Reddy S; Kumar R; Yang H; Alavi A; Zhuang H
Clin Nucl Med; 2007 Feb; 32(2):101-5. PubMed ID: 17242561
[TBL] [Abstract][Full Text] [Related]
16. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
Bryant AS; Cerfolio RJ
Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
[TBL] [Abstract][Full Text] [Related]
17. [Use of positron-emission tomography with F18-fluorodeoxyglucose for the assessment of lung lesions suspicious of malignancy].
Jofré MJ; Massardo T; González P; Canessa J; Sierralta P; Humeres P; Galaz R; Valdebenito R
Rev Med Chil; 2005 May; 133(5):583-92. PubMed ID: 15970984
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography imaging in nonmalignant thoracic disorders.
Alavi A; Gupta N; Alberini JL; Hickeson M; Adam LE; Bhargava P; Zhuang H
Semin Nucl Med; 2002 Oct; 32(4):293-321. PubMed ID: 12524653
[TBL] [Abstract][Full Text] [Related]
19. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of imaging proliferative activity in lung nodules.
Buck AK; Hetzel M; Schirrmeister H; Halter G; Möller P; Kratochwil C; Wahl A; Glatting G; Mottaghy FM; Mattfeldt T; Neumaier B; Reske SN
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):525-33. PubMed ID: 15599526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
